Evgeny M Krupitsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2648070/publications.pdf Version: 2024-02-01

		117453	106150
142	4,896	34	65
papers	citations	h-index	g-index
152	152	152	5071
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Assessment of cognitive functions in individuals with substance use disorder and HIV. HIV Infection and Immunosuppressive Disorders, 2022, 13, 21-32.	0.1	0
2	Stigma and ART initiation among people with HIV and a lifetime history of illicit drug use in Saint-Petersburg, Russia–A prospective cohort analysis. International Journal of Drug Policy, 2022, 102, 103600.	1.6	7
3	Sleep Disturbances in Patients with Alcohol Dependence with and without Tobacco Use. Psychiatry, 2022, 20, 68-78.	0.2	0
4	Linking HIV-positive people in addiction care to HIV services in St. Petersburg, Russia – Mixed-methods implementation study of strengths-based case management. Global Public Health, 2021, 16, 1711-1723.	1.0	4
5	HIV and Substance Use Stigma, Intersectional Stigma and Healthcare Among HIV-Positive PWID in Russia. AIDS and Behavior, 2021, 25, 2815-2826.	1.4	27
6	Per-protocol analysis of the ZINC trial for HIV disease among alcohol users. Trials, 2021, 22, 226.	0.7	2
7	Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, , 1-10.	0.6	1
8	The Hepatitis C Continuum of Care Among HIV-Positive Persons with Heavy Alcohol Use in St. Petersburg, Russia. AIDS and Behavior, 2021, 25, 2533-2541.	1.4	0
9	Features of providing addiction medical care during the pandemic COVID-19. V M Bekhterev Review of Psychiatry and Medical Psychology, 2021, 55, 45-51.	0.1	2
10	Lack of Association Between Recent Cannabis Use and Advanced Liver Fibrosis Among HIV-positive Heavy Drinkers. Current HIV Research, 2021, 19, 324-331.	0.2	2
11	Hazardous Alcohol Use, Impulsivity, and HIVâ€Risk Behavior Among HIVâ€Positive Russian Patients With a History of Injection Drug Use. American Journal on Addictions, 2021, 30, 164-172.	1.3	2
12	Levels of plasma soluble CD14 in HIV-positive patients during opioid withdrawal syndrome. Infectious Diseases: News, Opinions, Training, 2021, 10, 45-52.	0.1	0
13	Addressing intersectional stigma as a care barrier for HIV-positive people who inject drugs: Design of an RCT in St. Petersburg, Russia. Contemporary Clinical Trials Communications, 2021, 24, 100861.	0.5	7
14	Opioid use and dropout from extendedâ€release naltrexone in a controlled trial: implications for mechanism. Addiction, 2020, 115, 239-246.	1.7	17
15	Liver fibrosis and accelerated immune dysfunction (immunosenescence) among HIV-infected Russians with heavy alcohol consumption - an observational cross-sectional study. BMC Gastroenterology, 2020, 20, 1.	0.8	26
16	Design of a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia. Contemporary Clinical Trials Communications, 2020, 19, 100625.	0.5	8
17	Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al . (2020): Opioid use and dropout from extendedâ€release naltrexone in a controlled trial: implications for mechanism. Addiction, 2020, 115, 2188-2190.	1.7	0
18	Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use. JAMA Network Open, 2020, 3, e204330.	2.8	20

#	Article	IF	CITATIONS
19	Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic. Brain Stimulation, 2020, 13, 1124-1149.	0.7	78
20	Design of a randomized controlled trial to Link Infectious and Narcology Care (LINC-II) in St. Petersburg, Russia. Addiction Science & Clinical Practice, 2020, 15, 1.	1.2	11
21	The prevalence of the sleep disturbances among the patients with substance use disorders. Bulletin of Siberian Medicine, 2020, 18, 26-35.	0.1	3
22	DOPAMINE RECEPTOR D2 (DRD2) IN PERIPHERAL BLOOD LYMPHOCYTES AS BIOMARKER OF RESPONSE TO ANTIPSYCHOTIC MEDICATION. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2020, 27, 45-56.	0.0	0
23	Aberrant alternative splicing of HTR2A exon II in peripheral blood lymphocytes of drug-naÃ⁻ve schizophrenic patients. Heliyon, 2020, 6, e05809.	1.4	1
24	Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead. Neuroscience and Biobehavioral Reviews, 2019, 104, 118-140.	2.9	198
25	Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naÃ ⁻ ve persons with alcohol use in Russia. PLoS ONE, 2019, 14, e0218852.	1.1	14
26	Association between alcohol use and inflammatory biomarkers over time among younger adults with HIV—The Russia ARCH Observational Study. PLoS ONE, 2019, 14, e0219710.	1.1	22
27	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. Molecular Psychiatry, 2019, 24, 1099-1111.	4.1	11
28	Evolution of illicit opioid use among people with HIV infection in St Petersburg, Russia, in the period 2004–2015. HIV Medicine, 2019, 20, 450-455.	1.0	2
29	Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Lancet HIV,the, 2019, 6, e221-e229.	2.1	13
30	A strengths-based case management intervention to link HIV-positive people who inject drugs in Russia to HIV care. Aids, 2019, 33, 1467-1476.	1.0	16
31	Design of a randomized controlled trial of zinc supplementation to improve markers of mortality and HIV disease progression in HIV-positive drinkers in St. Petersburg, Russia. HIV Clinical Trials, 2018, 19, 101-111.	2.0	14
32	Comprehensive Women-Centered Treatment for Psychoactive Substance Use in the Republic of Georgia: Outcomes of a Randomized Clinical Trial. International Journal of Mental Health and Addiction, 2018, 16, 1249-1260.	4.4	2
33	Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology, 2018, 142, 72-82.	2.0	97
34	Use of an android phone application for automated text messages in international settings: A case study in an HIV clinical trial in St. Petersburg, Russia. Clinical Trials, 2018, 15, 36-43.	0.7	1
35	2232. Zinc deficiency and advanced liver fibrosis among HIV/HCV co-infected persons in Russia. Open Forum Infectious Diseases, 2018, 5, S660-S660.	0.4	0
36	The Influence of Rs6311 and Rs6313 Polymorphisms of Serotonin 2a Receptor Gene (HTR2A) on Its mRNA and Protein Levels in Peripheral Blood Leukocytes in Treatment with Antipsychotics. Cell and Tissue Biology, 2018, 12, 382-390.	0.2	3

#	Article	IF	CITATIONS
37	Addictionâ€related interactions of pregabalin with morphine in mice and humans: reinforcing and inhibiting effects. Addiction Biology, 2018, 23, 945-958.	1.4	28
38	Depression and smoking characteristics among HIV-positive smokers in Russia: A cross-sectional study. PLoS ONE, 2018, 13, e0189207.	1.1	5
39	Psychometric Properties and Factor Structure of the Russian Version of the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Counseling Psychology and Psychotherapy, 2018, 26, 80-104.	0.7	0
40	Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia. Drug and Alcohol Dependence, 2017, 172, 60-65.	1.6	5
41	HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking. AIDS and Behavior, 2017, 21, 2618-2627.	1.4	12
42	HIV Stigma and Unhealthy Alcohol Use Among People Living with HIV in Russia. AIDS and Behavior, 2017, 21, 2609-2617.	1.4	31
43	Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/AIDS who inject drugs. International Journal of Drug Policy, 2017, 39, 114-120.	1.6	6
44	Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome, 2017, 5, 141.	4.9	296
45	Food Insecurity, HIV Disease Progression and Access to Care Among HIV-Infected Russians not on ART. AIDS and Behavior, 2017, 21, 3486-3495.	1.4	7
46	Pain and Risk Behaviors Among HIV-Infected Persons in St. Petersburg, Russia. AIDS and Behavior, 2017, 21, 1775-1781.	1.4	4
47	Antagonist Treatment for Opioid Dependence: Promise and Hurdles. Current Treatment Options in Psychiatry, 2017, 4, 221-230.	0.7	1
48	Alcohol Use and Food Insecurity Among People Living with HIV in Mbarara, Uganda and St. Petersburg, Russia. AIDS and Behavior, 2017, 21, 724-733.	1.4	8
49	"lt is easier for me to shoot upâ€ı stigma, abandonment, and why HIV-positive drug users in Russia fail to link to HIV care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 559-563.	0.6	39
50	Impact of illicit opioid use on T cell subsets among HIV-infected adults. PLoS ONE, 2017, 12, e0176617.	1.1	4
51	Role of substance use in HIV care cascade outcomes among people who inject drugs in Russia. Addiction Science & Clinical Practice, 2017, 12, 30.	1.2	14
52	Sexual violence from police and HIV risk behaviours among HIVâ€positive women who inject drugs in St. Petersburg, Russia–Âa mixed methods study. Journal of the International AIDS Society, 2016, 19, 20877.	1.2	21
53	Mortality in HIV-Infected Alcohol and Drug Users in St. Petersburg, Russia. PLoS ONE, 2016, 11, e0166539.	1.1	12
54	Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg. Hepatology, Medicine and Policy, 2016, 1, .	1.7	14

#	Article	IF	CITATIONS
55	Psychiatric Distress, Drug Use, and HIV Viral Load Suppression in Russia. AIDS and Behavior, 2016, 20, 1603-1608.	1.4	12
56	Effects of Heavy Drinking on T ell Phenotypes Consistent with Immunosenescence in Untreated <scp>HIV</scp> Infection. Alcoholism: Clinical and Experimental Research, 2016, 40, 1737-1743.	1.4	3
57	Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. American Journal of Drug and Alcohol Abuse, 2016, 42, 614-620.	1.1	77
58	Linking Infectious and Narcology Care (LINC) in Russia: design, intervention and implementation protocol. Addiction Science & amp; Clinical Practice, 2016, 11, 10.	1.2	12
59	Proactive coping and spirituality among patients who left or remained in antiretroviral treatment in St Petersburg, Russian Federation. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 334-338.	0.6	8
60	Antagonist Models for Relapse Prevention and Reducing HIV Risk. Journal of NeuroImmune Pharmacology, 2016, 11, 401-407.	2.1	2
61	Feasibility and initial efficacy of a culturally sensitive women-centered substance use intervention in Georgia: Sex risk outcomes. Substance Abuse Treatment, Prevention, and Policy, 2015, 10, 47.	1.0	4
62	Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX). Journal of Addiction Medicine, 2015, 9, 238-243.	1.4	39
63	Comprehensive women-centered treatment for substance use disorders in Georgia: current status and future directions. Journal of Substance Use, 2015, 20, 367-374.	0.3	4
64	The Key Proteins of Dopaminergic Neurotransmission of Human Peripheral Blood Lymphocytes: Changed mRNA Level in Alcohol Dependence Syndrome. Bulletin of Experimental Biology and Medicine, 2015, 160, 271-274.	0.3	5
65	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. AIDS and Behavior, 2015, 19, 1089-1097.	1.4	9
66	Women Who Inject Drugs in the Republic of Georgia: In Their Own Words. Journal of Psychoactive Drugs, 2015, 47, 71-79.	1.0	9
67	Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 86-92.	0.6	28
68	<scp>HERMITAGE</scp> —a randomized controlled trial to reduce sexually transmitted infections and <scp>HIV</scp> risk behaviors among <scp>HIV</scp> â€infected <scp>R</scp> ussian drinkers. Addiction, 2015, 110, 80-90.	1.7	35
69	Use of Different Drug Formulations of Opioid Antagonist (Naltrexone) to Treat Opioid Dependence in Russia. , 2015, , 521-530.		1
70	Process and Product in Cross-Cultural Treatment Research: Development of a Culturally Sensitive Women-Centered Substance Use Intervention in Georgia. Journal of Addiction, 2014, 2014, 1-12.	0.9	6
71	Punitive policing and associated substance use risks among HIVâ€positive people in Russia who inject drugs. Journal of the International AIDS Society, 2014, 17, 19043.	1.2	37
72	Lost-to-care and engaged-in-care HIV patients in Leningrad Oblast, Russian Federation: barriers and facilitators to medical visit retention. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1249-1257.	0.6	22

#	Article	IF	CITATIONS
73	The influence of depressive symptoms on alcohol use among HIV-infected Russian drinkers. Drug and Alcohol Dependence, 2014, 134, 85-91.	1.6	12
74	Depressive Symptoms and Antiretroviral Therapy (ART) Initiation Among HIV-Infected Russian Drinkers. AIDS and Behavior, 2014, 18, 1085-1093.	1.4	15
75	Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, Russia. Drug and Alcohol Dependence, 2014, 144, 87-92.	1.6	22
76	Cannabis Withdrawal in Patients with and without Opioid Dependence. Substance Abuse, 2014, 35, 230-234.	1.1	8
77	Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1013-1018.	0.6	11
78	Factors Associated With Study Attrition Among HIV-Infected Risky Drinkers in St. Petersburg, Russia. HIV Clinical Trials, 2014, 15, 116-125.	2.0	2
79	Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications. International Journal of Transpersonal Studies, 2014, 33, 84-140.	0.2	20
80	Twice Stigmatized: Provider's Perspectives on Drug-Using Women in the Republic of Georgia. Journal of Psychoactive Drugs, 2013, 45, 1-9.	1.0	34
81	Nondisclosure of HIV Infection to Sex Partners and Alcohol's Role: A Russian Experience. AIDS and Behavior, 2013, 17, 390-398.	1.4	20
82	Access to treatment for substance-using women in the Republic of Georgia: Socio-cultural and structural barriers. International Journal of Drug Policy, 2013, 24, 566-572.	1.6	41
83	Naltrexone with or without guanfacine for preventing relapse to opiate addiction in StPetersburg, Russia. Drug and Alcohol Dependence, 2013, 132, 674-680.	1.6	34
84	Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. Drug and Alcohol Dependence, 2013, 132, 74-80.	1.6	20
85	Injectable extendedâ€release naltrexone (<scp>XR</scp> â€ <scp>NTX</scp>) for opioid dependence: longâ€term safety and effectiveness. Addiction, 2013, 108, 1628-1637.	1.7	98
86	Pain is associated with heroin use over time in <scp>HIV</scp> â€infected <scp>R</scp> ussian drinkers. Addiction, 2013, 108, 1779-1787.	1.7	18
87	Associations between partner violence perpetration and history of STI among HIV-infected substance using men in Russia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 646-651.	0.6	13
88	History of intimate partner violence is associated with sex work but not sexually transmitted infection among HIV-positive female drinkers in Russia. International Journal of STD and AIDS, 2013, 24, 287-292.	0.5	8
89	Antagonists for the Treatment of Opioid Dependence. , 2013, , 427-438.		3
90	Sexually transmitted infections among HIV-infected heavy drinkers in St Petersburg, Russia. International Journal of STD and AIDS, 2012, 23, 853-858.	0.5	12

#	Article	IF	CITATIONS
91	Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial. American Journal of Psychiatry, 2012, 169, 531-536.	4.0	79
92	Hostility and Anger in Patients Dependent on Different Psychoactive Drugs. Activitas Nervosa Superior, 2012, 54, 125-134.	0.4	8
93	Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification. Neuropsychiatry, 2012, 2, 355-362.	0.4	0
94	Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence. Archives of General Psychiatry, 2012, 69, 973.	13.8	115
95	Double jeopardydrug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trial. Substance Abuse Treatment, Prevention, and Policy, 2012, 7, 1.	1.0	61
96	Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet, The, 2011, 377, 1506-1513.	6.3	451
97	Promise of extended-release naltrexone is a red herring – Authors' reply. Lancet, The, 2011, 378, 663-664.	6.3	3
98	Injectable extended-release naltrexone for opioid dependence. Lancet, The, 2011, 378, 665.	6.3	22
99	Practices and Attitudes of Addiction Treatment Providers in the Russian Federation. Journal of Addiction Research & Therapy, 2011, 02, .	0.2	8
100	A sequencingâ€based survey of functional <i>APAF1</i> alleles in a large sample of individuals with affective illness and population controls. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 332-335.	1.1	0
101	Long-acting depot formulations of naltrexone for heroin dependence: a review. Current Opinion in Psychiatry, 2010, 23, 210-214.	3.1	55
102	Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available. Current Psychiatry Reports, 2010, 12, 448-453.	2.1	95
103	Addiction treatment in Russia. Lancet, The, 2010, 376, 1145.	6.3	9
104	Binge Drinking and Unsafe Sex: A Study of Narcology Hospital Patients from St. Petersburg, Russia. Substance Abuse, 2009, 30, 213-222.	1.1	7
105	Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. International Journal of Drug Policy, 2009, 20, 270-276.	1.6	41
106	Correlates of Any Condom Use Among Russian Narcology Patients Reporting Recent Unprotected Sex. AIDS and Behavior, 2009, 13, 310-317.	1.4	7
107	Psychosocial and contextual correlates of opioid overdose risk among drug users in St. Petersburg, Russia. Harm Reduction Journal, 2009, 6, 17.	1.3	15
108	Infectious Diseases And Medical Complications Of Drug Abuse- Part 1: Naltrexone treatment and HIV risk reduction for heroin addiction: 10-years Penn-Pavlov experience. Canadian Journal of Addiction, 2009, 1, 27-28.	0.2	0

#	Article	IF	CITATIONS
109	Implications of Cannabis Use and Heavy Alcohol Use on HIV Drug Risk Behaviors in Russian Heroin Users. AIDS and Behavior, 2008, 12, 662-669.	1.4	11
110	Mitigating risky sexual behaviors among Russian narcology hospital patients: the PREVENT (Partnership to Reduce the Epidemic Via Engagement in Narcology Treatment) randomized controlled trial. Addiction, 2008, 103, 1474-1483.	1.7	19
111	Behavioral Assessments in Russian Addiction Treatment Inpatients: A Comparison of Audio Computer-Assisted Self-Interviewing and Interviewer-Administered Questionnaires. HIV Clinical Trials, 2008, 9, 247-253.	2.0	5
112	Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence. Journal of Psychoactive Drugs, 2007, 39, 13-19.	1.0	111
113	Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients. American Journal of Psychiatry, 2007, 164, 519-523.	4.0	106
114	Nonverbal behavior of human addicts: Multimetric analysis. Addictive Behaviors, 2007, 32, 2260-2267.	1.7	3
115	Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use. Drug and Alcohol Dependence, 2007, 90, 25-38.	1.6	86
116	Mutation screen of theCAD2 gene and association study of alcoholism in three populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 183-192.	1.1	23
117	Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136008-???.	1.4	103
118	Multidimensionality of the Alcohol Withdrawal Symptom Checklist: A Factor Analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136010-???.	1.4	50
119	Gender Differences in Neurocognitive Functioning Among Alcohol-Dependent Russian Patients. Alcoholism: Clinical and Experimental Research, 2007, 31, 745-754.	1.4	38
120	HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Services Research, 2007, 7, 108.	0.9	67
121	Ketamine-Enhanced Psychotherapy: Preliminary Clinical Observations on its Effects in Treating Death Anxiety. International Journal of Transpersonal Studies, 2007, 26, 1-17.	0.2	27
122	Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2006, 31, 319-328.	1.5	95
123	Association between two µ-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Human Molecular Genetics, 2006, 15, 807-819.	1.4	155
124	Ketamine Enhanced Psychotherapy: Preliminary Clinical Observations on Its Effectiveness in Treating Alcoholism Humanistic Psychologist, 2006, 34, 399-422.	0.2	26
125	Co-Morbidity of Infectious and Addictive Diseases in St. Petersburg and the Leningrad Region, Russia. European Addiction Research, 2006, 12, 12-19.	1.3	46
126	Association Between Alcoholism and ??-Amino Butyric Acid ??2 Receptor Subtype in a Russian Population. Alcoholism: Clinical and Experimental Research, 2005, 29, 493-498.	1.4	188

#	Article	IF	CITATIONS
127	Alcohol use and HIV risk behaviors among HIV-infected hospitalized patients in St. Petersburg, Russia. Drug and Alcohol Dependence, 2005, 79, 251-256.	1.6	46
128	The onset of HIV infection in the Leningrad region of Russia: a focus on drug and alcohol dependence. HIV Medicine, 2004, 5, 30-33.	1.0	33
129	Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2004, 26, 285-294.	1.5	96
130	Neurobiological Approach to Treatment of Addiction. Addictive Disorders and Their Treatment, 2004, 3, 43-49.	0.5	0
131	NMDA Receptor Antagonism and the Ethanol Intoxication Signal. Annals of the New York Academy of Sciences, 2003, 1003, 176-184.	1.8	130
132	Effects of Citalopram Treatment of Protracted Withdrawal (Syndrome of Anhedonia) in Patients with Heroin Addiction. Addictive Disorders and Their Treatment, 2002, 1, 29-33.	0.5	55
133	A Pilot Study of Memantine Effects on Protracted Withdrawal (Syndrome of Anhedonia) in Heroin Addicts. Addictive Disorders and Their Treatment, 2002, 1, 143-146.	0.5	20
134	Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment, 2002, 23, 273-283.	1.5	159
135	Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists. Neuropsychopharmacology, 2001, 25, 936-947.	2.8	51
136	Prevention of Suicide by Naltrexone in a Recently Detoxified Heroin Addict. European Addiction Research, 2001, 7, 87-88.	1.3	9
137	Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research. Journal of Psychoactive Drugs, 1997, 29, 165-183.	1.0	174
138	Amelioration of stress in chemical dependency detoxification by transcranial electrostimulation. Stress and Health, 1994, 10, 115-126.	0.7	6
139	Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence, 1993, 33, 157-163.	1.6	87
140	The Combination of Psychedelic and Aversive Approaches in Alcoholism Treatment. Alcoholism Treatment Quarterly, 1992, 9, 99-105.	0.5	33
141	The administration of transcranial electric treatment for affective disturbances therapy in alcoholic patients. Drug and Alcohol Dependence, 1991, 27, 1-6.	1.6	34
142	Impulsivity and linkage to HIV Care among People living with HIV in St. Petersburg, Russia. AIDS and Behavior, 0, , .	1.4	0